article thumbnail

Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains

CFO News Room

Merck’s newly authorized molnupiravir treatment logged sales of $952 million in the fourth quarter, the first period when the drug contributed revenue. Meanwhile, sales of Covid-19 antibodies for Lilly grew by 22% year over year to $1.06 Regeneron Pharmaceuticals Inc. Overall, Merck’s sales for October through December were $13.52

Sales 130
article thumbnail

Netflix, Alphabet, Nordstrom, PagerDuty, more

CFO News Room

While Netflix missed earnings expectations, it added more subscribers than analysts were forecasting. ” Eli Lilly — Shares of the pharmaceutical company slumped more than 1% in premarket after the U.S. ” Eli Lilly — Shares of the pharmaceutical company slumped more than 1% in premarket after the U.S. year over year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Six Flags, Rivian, Bumble, Coinbase, Dutch Bros and more

CFO News Room

Bumble – Shares of the company known for its dating platforms added 10% even after Bumble issued a weak current quarter revenue forecast and missed expectations. Fair Isaac also issued guidance that beat a StreetAccount forecast. after it beat expectations for the quarter and raised its full-year forecast. Source link.

article thumbnail

Amazon, Snap, Ford and more

CFO News Room

Check out the companies making headlines before the bell: Regeneron Pharmaceuticals (REGN) – The drugmaker reported adjusted quarterly earnings of $23.72 Revenue also topped the forecast on strong sales of the company’s Covid-19 antibody therapy as well as its eye drug Eylea. per share, beating the $18.35

article thumbnail

Uber, Abiomed, Peloton, Carvana, Molson Coors and more

CFO News Room

Pfizer – Shares of the pharmaceutical giant jumped nearly 3% after the company reported stronger-than-expected earnings and issued an improved financial outlook. Pfizer said strong demand for its older drugs helped offset a drop in sales of its Covid-related products. billion forecast. J&J shares fell 1%. Source link.

article thumbnail

CrowdStrike, Horizon Therapeutics, Petco and more

CFO News Room

Horizon Therapeutics — The pharmaceutical company’s shares soared 26% after Horizon said it was in preliminary talks about a possible sale with several large pharma companies, including Amgen, Sanofi and Johnson & Johnson’s Janssen Global Services unit. Its adjusted EPS was in-line with expectations.

article thumbnail

Snap Seeks Ads From Pharmaceutical Companies

PYMNTS

A director of health for Snap, along with the company’s sales lead for health, spoke at the event. “Be loss per share, which was better than the Street’s forecast of $0.07. Snap revenues hit $390 million versus the $378 million forecast pre-earnings release. The news comes after Snap Inc. Snap posted $0.04